According to a recent news feature from LABIOTECH, Sellas Life Sciences Group, based in Switzerland, has just received orphan drug status approval by the United States Food and Drug Administration (FDA) for its new drug known as WT1 vaccine.
WT1 vaccine is an immunotherapeutic cancer vaccine that is being developed to prevent two different types of cancer that generally affect the lungs and surrounding tissues. Those cancers are malignant pleural mesothelioma (caused by asbestos exposure in nearly all cases) and acute myeloid leukemia (AML). So far, there have been phase II trails with the drug on both conditions, and there have been what are known as positive top line results during this course of these phase II clinical trials. Continue reading